Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions
Launched by PSYRIN INC. · Feb 11, 2025
Trial Information
Current as of July 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Outpatient status
- • 2. Men and women aged 18-68 years
- • 3. Capable and willing to provide informed consent
- • 4. Able to adhere to the treatment schedule
- • 5. Stable on medication for at least 2 months with no anticipated changes during the study period
- • 6. Diagnosis of MDD, PTSD, or BD
- • 7. Eligible for and scheduled to receive TMS or Spravato (esketamine) treatment to alleviate symptoms of MDD, PTSD, GAD, OCD or BD
- • 8. Fluent in English
- • 9. Access to a stable internet connection and an electronic device with a microphone for voice recording
- Exclusion Criteria:
- • 1. Use of any investigational drug within four weeks of the baseline visit
- • 2. If participating in psychotherapy, the patient must have been in stable treatment for at least three months before study entry, with no anticipated changes in the frequency of therapeutic sessions or therapeutic focus during the TMS or Spravato treatment.
- • 3. Intoxication during speech assessments
- • 4. Cognitive impairment that would interfere with study participation or data quality
- • 5. Lack of fluency in English
About Psyrin Inc.
Psyrin Inc. is an innovative clinical trial sponsor dedicated to advancing mental health therapies through rigorous scientific research and development. With a focus on neuropsychiatric disorders, Psyrin leverages cutting-edge methodologies and a patient-centered approach to deliver impactful solutions. The company collaborates with leading academic institutions and healthcare professionals to design and execute clinical trials that prioritize safety, efficacy, and ethical standards. Committed to transforming the landscape of mental health treatment, Psyrin Inc. strives to bring novel therapies from the laboratory to the clinic, ultimately improving patient outcomes and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sunnyvale, California, United States
New York City, New York, United States
Patients applied
Trial Officials
Julianna Olah, B.Sc., M.A., M.Sc., Ph.D.
Study Director
Psyrin Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported